Pathophysiologically based treatment interventions in schizophrenia925 - 932 David A Lewis & Guillermo Gonzalez-Burgos Nature Medicinedoi:10.1038/nm1478 Abstract|Full text|PDF
(64K)
New approaches to antidepressant drug discovery: beyond monoamines137-151 Olivier Berton and Eric J. Nestler Nature Reviews Neurosciencedoi:10.1038/nrn1846 Abstract|Full text|PDF
(225K)
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations133�146 T. Scott Stroup, Wayne M. Alves, Robert M. Hamer and Jeffrey A. Lieberman Nature Reviews Drug Discoverydoi:10.1038/nrd1956 Abstract|Full text|PDF
(225K)
Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice662�666 Iiris Hovatta, Richard S. Tennant, Robert Helton, Robert A. Marr, Oded Singer, Jeffrey M. Redwine, Julie A. Ellison, Eric E. Schadt, Inder M. Verma, David J. Lockhart and Carrolee Barlow Naturedoi:10.1038/nature04250 Abstract|Full text|PDF
(225K)
Altered neuregulin 1–erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia824-828 Nature Medicinedoi:10.1038/nm1418 Abstract|Full text|PDF
(64K)
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant actionp519-525 Nadia M Tsankova, Olivier Berton, William Renthal, Arvind Kumar, Rachel L Neve and Eric J Nestler Nature Neurosciencedoi:10.1038/nn1659 Abstract|Full text|PDF
(74K)
